FUTURE study

Multicenter study evaluating Feasibility & Usefulness of TEG6s PlateletMapping dUring Flow diverteR stEnting - FUTURE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs052210149

Enrollment

300

Registered

2022-01-07

Start date

2022-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unruptured cerebral aneurysm

Interventions

Blood test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Over 20 years old and more at the time of consent acquisition 2) Patients planning to undergo Flow diverter placement for unruptured cerebral aneurysm 3) Patients who have been taking or are scheduled to take aspirin and clopidogrel for more than 5 days before procedure 4) Patients with written consent

Exclusion criteria

Exclusion criteria: 1) Patients planning to change the content of antiplatelet drugs on the day of procedure 2) Patients on warfarin or direct oral anticoagulant (DOAC) 3) Patients contraindicated for MRI examination

Design outcomes

Primary

Measure	Time frame
Cut-off values for ADP-MA and ADP-inhibition% for the incidence rate of symptomatic stroke	—

Secondary

Measure	Time frame
Symptomatic ischemic stroke, high signal on diffusion-weighted images, hemorrhagic stroke	—

Contacts

Public ContactHirotoshi Imamura

National Cerebral and Cardiovascular Center Hospital

i-hiro@zg7.so-net.ne.jp+81-6-6170-1070

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026